Diabetic Cardiomyopathy

Overview

Journal Clin Sci (Lond)

Specialties Biochemistry
General Medicine
Science

Date 2009 Apr 15

PMID 19364331

Citations 67

Authors

Omar Asghar

Ahmed Al-Sunni

Kaivan Khavandi

Ali Khavandi

Sarah Withers

Adam Greenstein

Anthony M Heagerty

Rayaz A Malik

Affiliations

Soon will be listed here.

Abstract

Diabetic cardiomyopathy is a distinct primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. Epidemiological and clinical trial data have confirmed the greater incidence and prevalence of heart failure in diabetes. Novel echocardiographic and MR (magnetic resonance) techniques have enabled a more accurate means of phenotyping diabetic cardiomyopathy. Experimental models of diabetes have provided a range of novel molecular targets for this condition, but none have been substantiated in humans. Similarly, although ultrastructural pathology of the microvessels and cardiomyocytes is well described in animal models, studies in humans are small and limited to light microscopy. With regard to treatment, recent data with thiazolidinediones has generated much controversy in terms of the cardiac safety of both these and other drugs currently in use and under development. Clinical trials are urgently required to establish the efficacy of currently available agents for heart failure, as well as novel therapies in patients specifically with diabetic cardiomyopathy.

Citing Articles

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.

AlHabeeb W, Elasfar A, Kinsara A, Aljizeeri A, Jelaidan I, Alghalayini K J Saudi Heart Assoc. 2025; 36(4):385-407.

PMID: 39822337 PMC: 11737320. DOI: 10.37616/2212-5043.1407.

The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies.

Chen Z, Su X, Cao W, Tan M, Zhu G, Gao J Mar Drugs. 2024; 22(8).

PMID: 39195477 PMC: 11355449. DOI: 10.3390/md22080361.

MicroRNAs Targeting Critical Molecular Pathways in Diabetic Cardiomyopathy Emerging Valuable for Therapy.

Mathur P, Saxena S, Saxena B, Rani V Cardiovasc Hematol Agents Med Chem. 2024; 22(3):298-307.

PMID: 38265401 DOI: 10.2174/0118715257265947231129074526.

Ketogenic Diet Regulates Cardiac Remodeling and Calcium Homeostasis in Diabetic Rat Cardiomyopathy.

Lee T, Trang N, Lee T, Higa S, Kao Y, Chen Y Int J Mol Sci. 2023; 24(22).

PMID: 38003332 PMC: 10671812. DOI: 10.3390/ijms242216142.

Microvascular arterial disease of the brain and the heart: a shared pathogenesis.

Bradley C, Berry C QJM. 2023; 116(10):829-834.

PMID: 37467080 PMC: 10593384. DOI: 10.1093/qjmed/hcad158.

References

Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F . Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 2004; 18(7):828-35. DOI: 10.1096/fj.03-0736com. View

Barouch L, Berkowitz D, Harrison R, ODonnell C, Hare J . Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003; 108(6):754-9. DOI: 10.1161/01.CIR.0000083716.82622.FD. View

Svealv B, Olofsson E, Andersson B . Ventricular long-axis function is of major importance for long-term survival in patients with heart failure. Heart. 2007; 94(3):284-9. DOI: 10.1136/hrt.2006.106294. View

Jesmin S, Zaedi S, Shimojo N, Iemitsu M, Masuzawa K, Yamaguchi N . Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab. 2006; 292(4):E1030-40. DOI: 10.1152/ajpendo.00517.2006. View

Duncan E, Walker S, Ezzat V, Wheatcroft S, Li J, Shah A . Accelerated endothelial dysfunction in mild prediabetic insulin resistance: the early role of reactive oxygen species. Am J Physiol Endocrinol Metab. 2007; 293(5):E1311-9. DOI: 10.1152/ajpendo.00299.2007. View

Saito K, Nishi S, Kashima T, Tanaka H . Histologic and ultrastructural studies on the myocardium in spontaneously diabetic KK mice: a new animal model of cardiomyopathy. Am J Cardiol. 1984; 53(2):320-3. DOI: 10.1016/0002-9149(84)90446-6. View

Sundstrom J, Arnlov J, Stolare K, Lind L . Blood pressure-independent relations of left ventricular geometry to the metabolic syndrome and insulin resistance: a population-based study. Heart. 2007; 94(7):874-8. DOI: 10.1136/hrt.2007.121020. View

Liu Y, Cox S, Morita T, Kourembanas S . Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res. 1995; 77(3):638-43. DOI: 10.1161/01.res.77.3.638. View

Braz J, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R . PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004; 10(3):248-54. DOI: 10.1038/nm1000. View

10.

Kannel W, Hjortland M, CASTELLI W . Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1):29-34. DOI: 10.1016/0002-9149(74)90089-7. View

11.

Gangji A, Cukierman T, Gerstein H, Goldsmith C, Clase C . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389-94. DOI: 10.2337/dc06-1789. View

12.

Koya D, King G . Protein kinase C activation and the development of diabetic complications. Diabetes. 1998; 47(6):859-66. DOI: 10.2337/diabetes.47.6.859. View

13.

Xia Z, Kuo K, Nagareddy P, Wang F, Guo Z, Guo T . N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res. 2007; 73(4):770-82. DOI: 10.1016/j.cardiores.2006.11.033. View

14.

Sokos G, Nikolaidis L, Mankad S, Elahi D, Shannon R . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12(9):694-9. DOI: 10.1016/j.cardfail.2006.08.211. View

15.

Quinones M, GREENBERG B, Kopelen H, Koilpillai C, Limacher M, Shindler D . Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 2000; 35(5):1237-44. DOI: 10.1016/s0735-1097(00)00511-8. View

16.

Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P . Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):154-60. DOI: 10.1056/NEJM200001203420302. View

17.

Berry C, Brett M, Stevenson K, McMurray J, Norrie J . Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart. 2007; 94(3):296-304. DOI: 10.1136/hrt.2006.110999. View

18.

Richard D, Berra E, Pouyssegur J . Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Chem. 2000; 275(35):26765-71. DOI: 10.1074/jbc.M003325200. View

19.

Kawaguchi M, Asakura T, Saito F, Nemoto O, Maehara K, Miyake K . [Changes in diameter size and F-actin expression in the myocytes of patients with diabetes and streptozotocin-induced diabetes model rats]. J Cardiol. 2000; 34(6):333-9. View

20.

Devereux R, Roman M, Paranicas M, OGrady M, Lee E, Welty T . Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101(19):2271-6. DOI: 10.1161/01.cir.101.19.2271. View